MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4(7):566–577. https://doi.org/10.1038/nrm1151

Article  PubMed  CAS  Google Scholar 

Vafiadaki E, Glijnis PC, Doevendans PA, Kranias EG, Sanoudou D (2023) Phospholamban R14del disease: the past, the present and the future. Front Cardiovasc Med 10:1162205. https://doi.org/10.3389/fcvm.2023.1162205

Article  PubMed  PubMed Central  CAS  Google Scholar 

Doevendans PA, Glijnis PC, Kranias EG (2019) Leducq Transatlantic Network of Excellence to Cure Phospholamban-Induced Cardiomyopathy (CURE-PLaN). Circ Res 125(7):720–724. https://doi.org/10.1161/CIRCRESAHA.119.315077

Article  PubMed  CAS  Google Scholar 

Kranias EG, Doevendans PA, Glijnis PC, Hajjar RJ (2018) PLN Foundation A Foundation of patients for patients. Circul Res 123(12):1276–1278. https://doi.org/10.1161/Circresaha.118.314014

Article  CAS  Google Scholar 

Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW 2 et al (2006) A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A 103(5):1388–1393. https://doi.org/10.1073/pnas.0510519103

Cheung CC, Healey JS, Hamilton R, Spears D, Gollob MH, Mellor G, Steinberg C, Sanatani S, Laksman ZW, Krahn AD (2019) Phospholamban cardiomyopathy: a Canadian perspective on a unique population. Neth Heart J 27(4):208–213. https://doi.org/10.1007/s12471-019-1247-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jiang X, Xu Y, Sun J, Wang L, Guo X, Chen Y (2020) The phenotypic characteristic observed by cardiac magnetic resonance in a PLN-R14del family. Sci Rep 10(1):16478. https://doi.org/10.1038/s41598-020-73359-8

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tabata T, Kuramoto Y, Ohtani T, Miyawaki H, Miyashita Y, Sera F, Kioka H, Higo S, Asano Y, Hikoso S et al (2021) Phospholamban p.Arg14del cardiomyopathy: a Japanese Case Series. Intern Med 61(13):1987–1993. https://doi.org/10.2169/internalmedicine.8594-21

Article  PubMed  PubMed Central  Google Scholar 

van der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiesfeld AC, Cox MG, van Lochem LT, de Boer RA, Hofstra RM et al (2012) Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 14(11):1199–1207. https://doi.org/10.1093/eurjhf/hfs119

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hof IE, van der Heijden JF, Kranias EG, Sanoudou D, de Boer RA, van Tintelen JP, van der Zwaag PA, Doevendans PA (2019) Prevalence and cardiac phenotype of patients with a phospholamban mutation. Neth Heart J 27(2):64–69. https://doi.org/10.1007/s12471-018-1211-4

Article  PubMed  CAS  Google Scholar 

van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, Zwinderman AH, Pinto YM, Dit Deprez RH, Post JG, Tan HL et al (2014) Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet 7(4):455–465. https://doi.org/10.1161/CIRCGENETICS.113.000374

Article  PubMed  CAS  Google Scholar 

Badone B, Ronchi C, Lodola F, Knaust AE, Hansen A, Eschenhagen T, Zaza A (2021) Characterization of the PLN p.Arg14del mutation in Human Induced Pluripotent Stem Cell-Derived cardiomyocytes. Int J Mol Sci 22(24). https://doi.org/10.3390/ijms222413500

Cuello F, Knaust AE, Saleem U, Loos M, Raabe J, Mosqueira D, Laufer S, Schweizer M, van der Kraak P, Flenner F et al (2021) Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. EMBO Mol Med 13(6):e13074. https://doi.org/10.15252/emmm.202013074

Article  PubMed  PubMed Central  CAS  Google Scholar 

Eijgenraam TR, Boogerd CJ, Stege NM, Oliveira Nunes Teixeira V, Dokter MM, Schmidt LE, Yin X, Theofilatos K, Mayr M, van der Meer P et al (2021) Protein aggregation is an early manifestation of Phospholamban p.(Arg14del)-Related cardiomyopathy: development of PLN-R14del-Related cardiomyopathy. Circ Heart Fail 14(11):e008532. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008532

Article  PubMed  PubMed Central  CAS  Google Scholar 

Eijgenraam TR, Boukens BJ, Boogerd CJ, Schouten EM, van de Kolk CWA, Stege NM, Te Rijdt WP, Hoorntje ET, van der Zwaag PA, van Rooij E et al (2020) The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci Rep 10(1):9819. https://doi.org/10.1038/s41598-020-66656-9

Article  PubMed  PubMed Central  CAS  Google Scholar 

Feyen DAM, Perea-Gil I, Maas RGC, Harakalova M, Gavidia AA, Arthur Ataam J, Wu TH, Vink A, Pei J, Vadgama N et al (2021) Unfolded protein response as a compensatory mechanism and potential therapeutic target in PLN R14del cardiomyopathy. Circulation 144(5):382–392. https://doi.org/10.1161/CIRCULATIONAHA.120.049844

Article  PubMed  PubMed Central  CAS  Google Scholar 

Haghighi K, Gardner G, Vafiadaki E, Kumar M, Green LC, Ma J, Crocker JS, Koch S, Arvanitis DA, Bidwell P et al (2021) Impaired right ventricular Calcium Cycling is an early risk factor in R14del-Phospholamban arrhythmias. J Pers Med 11(6):502. https://doi.org/10.3390/jpm11060502

Article  PubMed  PubMed Central  Google Scholar 

Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, Kong CW, Rushing S, Hansen J, Ceholski D et al (2015) Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun 6:6955. https://doi.org/10.1038/ncomms7955

Article  PubMed  CAS  Google Scholar 

Kamel SM, van Opbergen CJM, Koopman CD, Verkerk AO, Boukens BJD, de Jonge B, Onderwater YL, van Alebeek E, Chocron S, Polidoro Pontalti C et al (2021) Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy. Nat Commun 12(1):7151. https://doi.org/10.1038/s41467-021-27461-8

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vafiadaki E, Haghighi K, Arvanitis DA, Kranias EG, Sanoudou D (2022) Aberrant PLN-R14del protein interactions intensify SERCA2a inhibition, driving impaired ca(2+) handling and Arrhythmogenesis. Int J Mol Sci 23(13):6947. https://doi.org/10.3390/ijms23136947

Article  PubMed  PubMed Central  CAS  Google Scholar 

Te Rijdt WP, van der Klooster ZJ, Hoorntje ET, Jongbloed JDH, van der Zwaag PA, Asselbergs FW, Dooijes D, de Boer RA, van Tintelen JP, van den Berg MP et al Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovasc Pathol 2017 Sep - Oct; 30:23–26. https://doi.org/10.1016/j.carpath.2017.05.004

Te Rijdt WP, van Tintelen JP, Vink A, van der Wal AC, de Boer RA, van den Berg MP, Suurmeijer AJ (2016) Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69(4):542–550. https://doi.org/10.1111/his.12963

Article  PubMed  Google Scholar 

Zanotti S, Ripolone M, Napoli L, Velardo D, Salani S, Ciscato P, Priori S, Kukavica D, Mazzanti A, Diamanti L et al (2023) Characterization of skeletal muscle biopsy and derived myoblasts in a patient carrying Arg14del mutation in Phospholamban Gene. Cells 12(10). https://doi.org/10.3390/cells12101405

Eijgenraam TR, Stege NM, Oliveira Nunes Teixeira V, de Brouwer R, Schouten EM, Grote Beverborg N, Sun L, Spater D, Knoll R, Hansson KM et al (2022) Antisense therapy attenuates Phospholamban p.(Arg14del) cardiomyopathy in mice and reverses protein aggregation. Int J Mol Sci 23(5):2427. https://doi.org/10.3390/ijms23052427

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rogalska M, Vafiadaki E, Erpapazoglou Z, Haghighi K, Green L, Mantzoros CS, Hajjar RJ, Tranter M, Karakikes I, Kranias EG et al (2023) Isoform changes of action potential regulators in the ventricles of arrhythmogenic phospholamban-R14del humanized mouse hearts metabolism. 138:155344. https://doi.org/10.1016/j.metabol.2022.155344

Vafiadaki E, Arvanitis DA, Pagakis SN, Papalouka V, Sanoudou D, Kontrogianni-Konstantopoulos A, Kranias EG (2009) The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival. Mol Biol Cell 20(1):306–318. https://doi.org/10.1091/mbc.E08-06-0587

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vafiadaki E, Sanoudou D, Arvanitis DA, Catino DH, Kranias EG, Kontrogianni-Konstantopoulos A (2007) Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. J Mol Biol 367(1):65–79. https://doi.org/10.1016/j.jmb.2006.10.057

Article  PubMed  CAS  Google Scholar 

Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675. https://doi.org/10.1038/nmeth.2089

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bolte S, Cordelieres FP (2006) A guided tour